$37.15+0.97 (+2.68%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Progyny (PGNY) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~26.7%/yr (FY21→FY25), net margin 4.5%, and free cash flow (~$191.8M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Capex step-up ($18.4M). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲10.4%
1,288.7
FY21→FY25CAGR +26.7%/yr
Net income ($M)▲7.7%
58.5
one-off year: see footnoteCAGR −2.9%/yr
Free cash flow ($M)▲10.4%
191.8
capex stepped upCAGR +68.3%/yr
Diluted EPS▲14.0%
0.65
buyback-liftedCAGR −0.4%/yr
What the receipts whisper · what a headline number hides
Share count
−10.5%
100.4mn → 89.9mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex step-up
$18.4M
▲241% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
Returns vs FCF
43%
$81.7M returned vs $191.8M of FCF in FY25. Buybacks covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
5¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 22.4% → 23.6%. Net margin 4.5% is above the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,338,672.0 | 1,288,661.0 | 1,167,221.0 | 1,088,598.0 | 786,913.0 | 500,621.0 | ▲10.4% | +26.7% |
Cost of revenue | 1,005,679.0 | 984,177.0 | 913,858.0 | 849,799.0 | 619,588.0 | 388,486.0 | ▲7.7% | +26.2% |
Gross profit | 332,993.0 | 304,484.0 | 253,363.0 | 238,799.0 | 167,325.0 | 112,135.0 | ▲20.2% | +28.4% |
Selling, general & admin | 136,199.0 | 147,094.0 | 121,960.0 | 117,127.0 | 98,327.0 | 59,616.0 | ▲20.6% | +25.3% |
Total operating expenses | 207,207.0 | 219,207.0 | 185,908.0 | 176,615.0 | 143,984.0 | 79,795.0 | ▲17.9% | +28.7% |
Operating incomefeeds ROC rank | 125,786.0 | 85,277.0 | 67,455.0 | 62,184.0 | 23,341.0 | 32,340.0 | ▲26.4% | +27.4% |
Other income, net | 6,504.0 | 10,155.0 | 15,747.0 | 8,507.0 | 1,100.0 | 95.0 | — | — |
Pretax income | 132,290.0 | 95,432.0 | 83,202.0 | 70,691.0 | 24,441.0 | 32,435.0 | ▲14.7% | +31.0% |
Income tax | 41,269.0 | 36,912.0 | 28,866.0 | 8,654.0 | −5,917.0 | −33,334.0 | ▲27.9% | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 91,021.0 | 58,520.0 | 54,336.0 | 62,037.0 | 30,358.0 | 65,769.0 | ▲7.7% | −2.9% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 1.09 | 0.65 | 0.57 | 0.62 | 0.30 | 0.66 | ▲14.0% | −0.4% |
Diluted shares (mn) | 81.17 | 89.86 | 95.45 | 100.67 | 99.96 | 100.36 | ▼5.9% | −2.7% |
| Margins | ||||||||
Gross margin9th pct in Healthcare | 24.9% | 23.6% | 21.7% | 21.9% | 21.3% | 22.4% | ▲1.9pp | +1.2pp |
Operating margin | 9.4% | 6.6% | 5.8% | 5.7% | 3.0% | 6.5% | ▲0.8pp | +0.2pp |
Net margin60th pct in Healthcare | 6.8% | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | ▼0.1pp | −8.6pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was −103% vs a 12% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was −24% vs a 12% norm for this window, likely a one-time item; see the filing.
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-27 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Progyny's revenue last fiscal year?
Progyny reported revenue of $1,288.7M in fiscal 2025, up 10.4% from fiscal 2024.
What was Progyny's net income?
Progyny reported net income of $58.5M in fiscal 2025, a net margin of 4.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

